Other Excitatory Amino Acids

Product #

Image

Description

Biochem/physiol Actions

Add to Cart

N5636 3-Nitropropionic acid ≥97% Excitotoxin shown to cause brain lesions similar to those of Huntington′s disease.
G9003 D-Glutamine ≥98% (TLC) Glutamine forms the central metabolite in amino acid transamination via a-ketoglutarate and glutamic acid. This amino acid is metabolized by different enzymes, such as glutaminase, present in liver, and glutamine synthetase, present in skeletal muscle. It is produced in the cytoplasm from other amino acids, predominantly from branched-chain amino acids and glutamate. It plays an essential role in ammonia metabolism and detoxification. Its skeletal muscle levels are significantly reduced post trauma, operation and inflammatory states. It servers as a prognostic marker in fatal sepsis during which its skeletal muscle levels are decreased by 90%.
H2775 DL-threo-β-Hydroxyaspartic acid  
C4418 L-Cysteinesulfinic acid monohydrate Putative excitatory amino acid neurotransmitter
G3126 L-Glutamine ReagentPlus®, ≥99% (HPLC) L-Glutamine is an essential amino acid that is a crucial component of culture media that serves as a major energy source for cells in culture. L-Glutamine is very stable as a dry powder and as a frozen solution. In liquid media or stock solutions, however, L-glutamine degrades relatively rapidly. Optimal cell performance usually requires supplementation of the media with L-glutamine prior to use.
M5379 L-Methionine sulfoximine Methionine sulfoximine (MSX) increases ornithine decarboxylase activity, decreases the survival rate in a model of transient cerebral ischemia, and inhibits glutamine synthetase activity.
76078 L-Methionine sulfoximine PharmaGrade, Manufactured under appropriate GMP controls for pharma or biopharmaceutical production.  
P7575 L-trans-Pyrrolidine-2,4-dicarboxylic acid ≥98% Selective inhibitor of glutamate uptake
C8679 Chicago Sky Blue 6B powder Chicago Sky Blue 6B is a large organic acid, structurally related to glutamate, that is a potent and efficient competitive inhibitor of vesicular glutamate uptake.
F0430 Fenobam ≥98% (HPLC), solid Fenobam is a potent, selective, noncompetitive glutamate mGluR5 receptor antagonist. Fenobam displays inverse agonist properties; blocks mGluR5 constitutive activity in vitro (IC50 = 87 nM, slightly weaker than MPEP). Fenobam acts at an allosteric modulatory site shared with MPEP and binds the mGlu5 receptor with Kd values of 54 and 31 nM for rat and human receptors, respectively. Fenobam belongs to a structurally different class than MPEP; devoid of GABAergic activity and thus typical benzodiazepine-like side effects; displays anxiolytic activity.
I2765 Ibotenic acid ~95%, solid Non-selective agonist with preference for NMDA glutamate receptors; neurotoxin; neuroexcitatory amino acid originally isolated from Amanita species.
M1694 MPPG ≥97% (NMR), solid Group III/II metabotropic glutamate (mGluR) receptor antagonist.
P7505 Putrescine dihydrochloride ≥98% (TLC) Binds to the polyamine modulatory site of the NMDA receptor and potentiates NMDA-induced currents; precursor of spermidine.
R116 Riluzole solid Glutamate release inhibitor; anticonvulsant
V1640 VU0155041 ≥98% (HPLC) VU0155041 is a mixed allosteric agonist/positive allosteric modulator (PAM) of mGluR4. VU0155041 is approximately 8-fold more potent than PHCCC and does not show any significant potentiator or antagonist activity at other mGluR subtypes. It is soluble in an aqueous vehicle and intracerebroventricular administration of 31-316 nmol of VU0155041 dose-dependently decreased haloperidol-induced catalepsy and reserpine-induced akinesia in rats. VU0155041 exhibits selectivity for mGluR4 relative to 67 different targets and does not affect the function of striatal NMDA receptors.
VU0155041 is a positive allosteric modulator of the metabotropic glutamate receptor subtype 4. It also shows some direct agonist activity, but at a site different from the glutamate binding site. /VU0155041 is approximately 8-fold more potent than PHCCC and enhances the activity of glutamate also about 8-fold. It shows promising anti-Parkinsonian effects in animal models of Parkinson′s disease.